Ideaya Biosciences, INC Form 4 insider transactions

IDEAYA Biosciences Chief Accounting Officer Andres Ruiz Briseno reports a 10b5-1 plan transaction involving the acquisition and sale of common stock.

IDEAYA Biosciences Director Wendy L. Yarno acquired 20,000 stock options with an exercise price of $30.57, vesting under specific conditions related to service and annual meetings.

IDEAYA Biosciences reports that Director Jeffrey Stein acquired 20,000 stock options.

IDEAYA Biosciences, Inc. reports that Director Terry J. Rosen acquired 20,000 stock options with an exercise price of $30.57.

IDEAYA Biosciences Director Scott W. Morrison acquired 20,000 stock options with an exercise price of $30.57, vesting under specific conditions.

IDEAYA Biosciences reports a Form 4 filing detailing the acquisition of stock options by Director Catherine J. Mackey.

IDEAYA Biosciences Director Malcolm Garret Hampton acquired 20,000 stock options with an exercise price of $30.57.

IDEAYA Biosciences Director Jeffrey Stein reported a planned acquisition of 50,000 shares of common stock on March 2, 2026, at a weighted average price of $32.9578.

IDEAYA Biosciences' Chief Financial Officer, Joshua Bleharski, was granted 170,000 stock options with a vesting schedule over four years.

IDEAYA Biosciences' Chief Scientific Officer, Michael Anthony White, was granted 190,000 stock options with an exercise price of $32.19, vesting over four years.

IDEAYA Biosciences' Chief Medical Officer, Darrin Beaupre, was granted 175,000 stock options with an exercise price of $32.19, vesting over four years.

IDEAYA Biosciences' Chief Commercial Officer, Stuart Dorman, was granted 155,000 stock options with an exercise price of $32.19, vesting over four years.

IDEAYA Biosciences, Inc. President and CEO Yujiro Hata was granted 600,000 stock options with an exercise price of $32.19, vesting over four years.

IDEAYA Biosciences' SVP and General Counsel, Douglas B. Snyder, reported acquiring common stock through an ESPP and a significant stock option grant.

IDEAYA Biosciences' SVP of Finance and Investor Relations, Andres Ruiz Briseno, increased his common stock holdings and received a significant stock option grant.

IDEAYA Biosciences, Inc. Director Wendy L. Yarno received a grant of 20,000 stock options with an exercise price of $21.78, aligning her interests with shareholder value.

Jeffrey Stein, a Director at IDEAYA Biosciences, Inc. (IDYA), was granted 20,000 stock options with an exercise price of $21.78, aligning his interests with shareholders.

IDEAYA Biosciences, Inc. Director Malcolm Garret Hampton was granted 20,000 stock options with an exercise price of $21.78, vesting over the next year.

IDEAYA Biosciences, Inc. Director Scott W. Morrison was granted 20,000 stock options with an exercise price of $21.78 per share, aligning his interests with shareholders.

Catherine J. Mackey, a Director at IDEAYA Biosciences, Inc., was granted 20,000 stock options with an exercise price of $21.78, aligning her interests with shareholder value.

IDEAYA Biosciences, Inc. Director Terry J. Rosen was granted 20,000 stock options with an exercise price of $21.78, vesting over the next year, as disclosed in a recent SEC Form 4 filing.

Darrin Beaupre, Chief Medical Officer of Ideaya Biosciences, acquired 185,000 stock options at an exercise price of $20.24 on February 27, 2025, according to a recent SEC Form 4 filing.

Stuart Dorman, Chief Commercial Officer of Ideaya Biosciences, acquired 15,000 stock options at an exercise price of $20.24 on February 27, 2025.

Andres Ruiz Briseno, SVP, Head of Finance and Investor Relations at IDEAYA Biosciences, acquired 75,000 stock options on February 27, 2025.

Michael Anthony White, Chief Scientific Officer of Ideaya Biosciences, acquired 185,000 stock options on February 27, 2025, at an exercise price of $20.24.

Douglas B. Snyder, SVP, General Counsel of Ideaya Biosciences, reports the acquisition of stock options for 33,000 shares of common stock on February 27, 2025.

Yujiro Hata, President and CEO of Ideaya Biosciences, Inc., reports the acquisition of 600,000 stock options at an exercise price of $20.24 on February 27, 2025.

Yujiro Hata, President and CEO of IDEAYA Biosciences, exercised stock options on February 18, 2025, acquiring 12,808 shares of common stock.

Douglas B. Snyder, SVP, General Counsel of Ideaya Biosciences, Inc., reported the acquisition of 140,000 stock options on September 26, 2024.

Jason Throne, Chief Legal Officer of Ideaya Biosciences, exercised stock options on June 27, 2024, acquiring a total of 53,484 shares of common stock.